

ASX ANNOUNCEMENT

10 April 2026

Little Green Pharma Ltd (ASX: LGP)

SCHEME APPROVED BY CANNATREK SHAREHOLDERS



Little Green Pharma Ltd (ASX:LGP) (**LGP** or the **Company**) provides the following update on the Company's proposed acquisition of 100% of the issued capital of Cannatrek Ltd (**Cannatrek**) by way of scheme of arrangement under Part 5.1 of the Corporations Act 2001 (Cth) (**Corporations Act**) (**Scheme**).

Capitalised terms used in this announcement have the meaning given to them in the Scheme Booklet, unless otherwise specified.

RESULTS OF THE SCHEME MEETING

LGP advises that the Scheme Resolution was passed by the Requisite Majority of Cannatrek Shareholders at the Scheme Meeting held on 10 April 2026.

In summary, 96.15% of Cannatrek Shareholders present and voting at the Scheme Meeting (in person or by proxy, attorney or corporate representative) were in favour of the Scheme Resolution, and 98.44% of the total number of votes cast by Cannatrek Shareholders at the Scheme Meeting were in favour of the Scheme Resolution.

Details of the valid proxies received and votes cast at the Scheme Meeting are set out in the attachment to this announcement.

Cannatrek will apply to the Federal Court of Australia for approval of the Scheme at a hearing scheduled at 9:30am (Melbourne time) on Friday, 24 April 2026 (**Second Court Hearing**). If the Court approves the Scheme at the Second Court Hearing, Cannatrek intends to lodge a copy of the Court orders with ASIC on the same day (Friday, 24 April 2026), when the Scheme will become Effective. It is expected that the Scheme will be implemented on Friday, 1 May 2026.

INDICATIVE TIMETABLE

The updated key dates and times for the Scheme are as follows:

Event	Date
Latest time and date for receipt of proxy forms and powers of attorney from LGP Shareholders for the LGP Shareholder Meeting	3:30pm (Perth time) on 20 April 2026
Time and date for determining eligibility of LGP Shareholders to vote at the LGP Shareholder Meeting	5:00pm (Perth time) on 20 April 2026
LGP Shareholder Meeting	3.30pm (Perth time) on 22 April 2026
Second Court Date for approval of the Scheme	9:30am (Melbourne time) on 24 April 2026
Effective Date Court order lodged with ASIC and announcement to the ASX by LGP	24 April 2026
Scheme Record Date for determining entitlements to Consideration Securities	7:00pm (Melbourne time) on 24 April 2026
Implementation Date and provision of Consideration Securities	1 May 2026

Notes:

- All dates following the date of the Scheme Meeting are indicative only and, among other things, are subject to all necessary approvals from the Court. Any changes to the above timetable (which may include an earlier or later date for the Second Court Hearing) will be announced through the ASX (by LGP) and notified via Boardroom, Cannatrek's Share Registry. Cannatrek may vary the timetable detailed above subject to the approval of such variation by LGP, the Court and ASIC where required.

This announcement has been authorised for release by the board of Little Green Pharma Ltd

For further information please contact:

**Alistair Warren
Company Secretary**

Little Green Pharma
E: cosec@lgp.global
T: +61 8 6280 0050

**Paul Long
Managing Director**

Little Green Pharma
E: p.long@lgp.global
T: +61 8 6280 0050



About Little Green Pharma

Little Green Pharma Ltd (ASX:LGP) is a leading global medicinal cannabis company with vertically integrated operations across Europe and Australia.

LGP has a diverse and growing portfolio of cannabis-based medicines, distributed across Australia and over 12 export markets via a network of wholesalers, pharmacies, clinics, and GPs. The Company generates revenue through both the sale of medicinal cannabis products and its domestic Health House distribution business, which allows it to capture value across the supply chain and to adapt to evolving regulatory environments while building defensible commercial positions in high-growth markets.

Operating three production facilities in Denmark and Australia – including the largest facility in Europe – LGP is the one of the top three suppliers in Australia, the largest supplier into France, and a significant supplier into Germany and the UK, positioning it as a key player in global medicinal cannabis markets.

With diversified revenue streams, a presence in over a dozen export markets, and a high net tangible asset position relative to its enterprise value, LGP offers investors leveraged exposure to global medicinal cannabis demand and a clear platform for scalable growth.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email to help reduce our costs and environmental footprint.

To easily update your communication preferences, visit:
www.computershare.com.au/easyupdate/lgp